Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target

Oncotarget

Volumn 3, Issue 9, 2012, Pages 998-1010

  Zhang, Fang ^a   Rothermund, Kristi ^a   Gangadharan, Sajithlal B ^a   Pommier, Yves ^b   Prochownik, Edward V ^a   Lazo, John S ^c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cancer stem cell; Compound library screening; Small molecule inhibitor; Topoisomerase I

Indexed keywords

3 (1 ADAMANTYL) 1 AMINOMETHYL 3,4 DIHYDRO 5,6 DIHYDROXY 1H 2 BENZOPYRAN; ANTINEOPLASTIC AGENT; BETA LAPACHONE; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CGP 74514A; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; MESSENGER RNA; ROTTLERIN; TOPOTECAN; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER STEM CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SPECIFICITY; GENE EXPRESSION; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR CELL DESTRUCTION;

EID: 84868612362     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.632     Document Type: Article

References (50)

1. Cho RW and Clarke MF. Recent advances in cancer stem cells. Curr Opin Genet Dev. 2008; 18:48-53.
2. Dick JE. Stem cell concepts renew cancer research. Blood. 2008; 112:4793-4807.
3. Wang JC and Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005; 15:494-501.
4. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E and Chang HY. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell. 2008; 2:333-344.
5. Wong DJ, Segal E and Chang HY. Stemness, cancer and cancer stem cells. Cell Cycle. 2008; 7:3622-3624.
6. Orkin SH and Zon LI. SnapShot: hematopoiesis. Cell. 2008; 132(4):712-712.
7. Al-Hajj M, Becker MW, Wicha M, Weissman I and Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004; 14(1):43-47.
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A Proc Natl Acad Sci U S A. 2003; 100:3983-3988.
9. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J, Chang HY, van de Rijn M, Shortliffe L and Weissman IL. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A. 2009; 106:14016-14021.
10. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur M-H, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009; 69:1302-1313.
11. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ and Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007; 1:313-323.
12. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M and Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005; 11:1154-1159.
13. Glinsky GV, Berezovska O and Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005; 115:1503-1521.
14. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, Liu S, Dontu G and Wicha MS. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat. 2010; 122:777-785.
15. Tanaka H, Nakamura M, Kameda C, Kubo M, Sato N, Kuroki S, Tanaka M and Katano M. The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells. Anticancer Res. 2009; 29:2147-2157.
16. Merchant AA and Matsui W. Targeting Hedgehog--a cancer stem cell pathway. Clin Cancer Res. 2010; 16:3130-3140.
17. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B and Miele L. Targeting Notch to target cancer stem cells. Clin Cancer Res. 2010; 16:3141-3152.
18. Takebe N, Harris PJ, Warren RQ and Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011; 8:97-106.
19. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG and Wicha MS. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009; 7:e1000121.
20. Korkaya H, Paulson A, Iovino F and Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008; 27:6120-6130.
21. Bonnet D and Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3:730-737.
22. Neering SJ, Bushnell T, Sozer S, Ashton J, Rossi RM, Wang P-Y, Bell DR, Heinrich D, Bottaro A and Jordan CT. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood. 2007; 110:2578-2585.
23. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA and Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138:645-659.
24. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704-715.
25. Sajithlal GB, Rothermund K, Zhang F, Dabbs DJ, Latimer JJ, Grant SG and Prochownik EV. Permanently blocked stem cells derived from breast cancer cell lines. Stem Cells. 2010; 28:1008-1018.
26. Kitchens CA, McDonald PR, Shun TY, Pollack IF and Lazo JS. Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens. J Pharm Exptl Therap. 2011; 339:851-858.
27. Li Y, Sun X, LaMont JT, Pardee AB and Li CJ. Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci USA. 2003; 100:2674-2678.
28. Li YZ, Li CJ, Pinto AV and Pardee AB. Release of mitochondrial cytochrome C in both apoptosis and necrosis induced by beta-lapachone in human carcinoma cells. Mol Med. 1999; 5:232-239.
29. Manna SK, Gad YP, Mukhopadhyay A and Aggarwal BB. Suppression of tumor necrosis factor-activated nuclear transcription factor-kappaB, activator protein-1, c-Jun N-terminal kinase, and apoptosis by beta-lapachone. Biochem Pharmacol. 1999; 57:763-774.
30. Miao XS, Zhong C, Wang Y, Savage RE, Yang RY, Kizer D, Volckova E, Ashwell MA and Chan TC. In vitro metabolism of beta-lapachone (ARQ 501) in mammalian hepatocytes and cultured human cells. Rapid Commun Mass Spectrom. 2009; 23:12-22.
31. Li CJ, Averboukh L and Pardee AB. beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem. 1993; 268:22463-22468.
32. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nature Rev Cancer. 2006; 6:789-802.
33. Chen BM, Chen JY, Kao M, Lin JB, Yu MH and Roffler SR. Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy. Gynecol Oncol. 2000; 79:272-280.
34. Magrini R, Bhonde MR, Hanski ML, Notter M, Scherübl H, Boland CR, Zeitz M and Hanski C. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer. 2002; 101:23-31.
35. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potmesil M. DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science. 1989; 246:1046-1048.
36. Dean M, Fojo T and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5:275-284.
37. Ding XW, Wu JH and Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010; 86:631-637.
38. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T and Bates SE. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 1999; 59:5938-5946.
39. Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, Robles AI, Varticovski L, Nagarajan M, Morrell A, Cushman M and Pommier Y. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res. 2007; 67:10397-10405.
40. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC and Kaufmann SH. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 1992; 52:2268-2278.
41. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS and Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1:555-567.
42. Pardee AB, Li YZ and Li CJ. Cancer therapy with beta-lapachone. Curr Cancer Drug Targets. 2002; 2:227-242.
43. Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, Minna JD, Bornmann WG, Gao J and Boothman DA. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci USA. 2007; 104:11832-11837.
44. Antony S, Kohlhagen G, Agama K, Jayaraman M, Cao S, Durrani FA, Rustum YM, Cushman M and Pommier Y. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol Pharmacol. 2005; 67:523-530.
45. Pommier Y and Cushman M. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol Cancer Therap. 2009; 8:1008-1014.
46. Graf P, Dolzblasz A, Würschum T, Lenhard M, Pfreundt U and Laux T. MGOUN1 encodes an Arabidopsis type IB DNA topoisomerase required in stem cell regulation and to maintain developmentally regulated gene silencing. Plant Cell. 2010; 22:716-728.
47. Champoux JJ. DNA topoisomerases: Structure, function an dmechanism. Annu Rev Biochem. 2001; 70:369-413.
48. Chen AY, Okunieff P, Pommier Y and Mitchell JB. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res. 1997; 57:1529-1536.
49. Holleran JL, Parise RA, Yellow-Duke AE, Egorin MJ, Eiseman JL, Covey JM and Beumer JHL. Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776. J Pharm Biomed Anal. 2010; 52:714-720.
50. Bansal P and Lazo JS. Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. Cancer Res. 2007; 67:3356-3363.